Literature DB >> 23560463

Methotrexate/iatrogenic lymphoproliferative disorders in rheumatoid arthritis: histology, Epstein-Barr virus, and clonality are important predictors of disease progression and regression.

Ayako Ichikawa1, Fumiko Arakawa, Junichi Kiyasu, Kensaku Sato, Hiroaki Miyoshi, Daisuke Niino, Yoshizo Kimura, Masanori Takeuchi, Maki Yoshida, Yukinao Ishibashi, Shinji Nakashima, Yasuo Sugita, Osamu Miura, Koichi Ohshima.   

Abstract

OBJECTIVES: Patients with rheumatoid arthritis (RA) may develop lymphoproliferative disorders (RA-LPD). Immunosuppressive states due to methotrexate (MTX) and Epstein-Barr virus (EBV) reactivation have been regarded as causes. Sometimes spontaneous regression occurs after withdrawal of MTX. The objective of this study was to identify factors predictive of relapse and survival in patients with RA-LPD, and spontaneous regression in patients with RA-LPD treated with MTX (MTX-LPD).
METHODS: We evaluated the clinicopathological features, clinical characteristics, and treatment outcomes in 102 cases of RA-LPD. In addition, EBV infection and clonality of immunoglobulin heavy chain gene (IGH) were analyzed by in situ hybridization and polymerase chain reaction, respectively.
RESULTS: The 102 cases included patients with diffuse large B-cell lymphoma (DLBCL; n = 53), Hodgkin lymphoma (n = 9), polymorphic B-cell LPD (n = 20), reactive lymphadenitis (n = 11), peripheral T-cell lymphoma (PTCL; n = 4), composite lymphoma (n = 2), and follicular lymphoma (n = 3). EBV was detected in 60% (56/93) of patients. Spontaneous regression occurred in 59% (28/47) of patients in whom MTX was withdrawn. Regression was associated with EBV positivity (P = 0.007) and non-DLBCL (P = 0.006), but not with MTX amount and other clinical features. Monoclonal bands of IGH were observed in 31 of 74 cases. In patients with DLBCL, poor disease-free survival (P = 0.05) was associated with clonality of IGH. In all patients, factors predictive of shorter survival were age (>70 yr) and histological type of DLBCL.
CONCLUSIONS: Histology, EBV positivity, and monoclonality of IGH are useful for predicting clinical outcomes in patients with RA-LPD.
© 2013 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23560463     DOI: 10.1111/ejh.12116

Source DB:  PubMed          Journal:  Eur J Haematol        ISSN: 0902-4441            Impact factor:   2.997


  69 in total

1.  Treatment of advanced stage methotrexate-associated lymphoproliferative disorders (MTX-LPDs) with methotrexate discontinuation.

Authors:  Yael Ross; Mohammad Kamran
Journal:  BMJ Case Rep       Date:  2018-12-13

2.  Identification of IG-clonality status as a pre-treatment predictor for mortality in patients with immunodeficiency-associated Epstein-Barr virus-related lymphoproliferative disorders.

Authors:  Walter J F M van der Velden; Loes Nissen; Marieke van Rijn; Jos Rijntjes; Anton de Haan; Lakshmi Venkatraman; Mark Catherwood; Hongxiang Liu; Hesham El-Daly; Lisette van de Laar; Moniek H C Craenmehr; J Han J M van Krieken; Wendy B C Stevens; Patricia J T A Groenen
Journal:  Haematologica       Date:  2014-12-19       Impact factor: 9.941

3.  Methotrexate-induced iatrogenic immunodeficiency-associated lymphoproliferative disorder causing hypercalcaemia.

Authors:  Monica Lee; Khoa Anh Nguyen; Robert Kaplan
Journal:  BMJ Case Rep       Date:  2019-05-31

4.  Nodal EBV-positive polymorphic B cell lymphoproliferative disorder with plasma cell differentiation: clinicopathological analysis of five cases.

Authors:  Akira Satou; Tetsuya Tabata; Yuka Suzuki; Yasuharu Sato; Ippei Tahara; Kunio Mochizuki; Naoki Oishi; Taishi Takahara; Tadashi Yoshino; Toyonori Tsuzuki; Shigeo Nakamura
Journal:  Virchows Arch       Date:  2020-11-09       Impact factor: 4.064

5.  Methotrexate-associated Classical Hodgkin Lymphoma Shows Distinct Clinicopathological Features but Comparable Clinical Outcomes With Sporadic Cases.

Authors:  Kota Yoshifuji; Yoshihiro Umezawa; Ayako Ichikawa; Ken Watanabe; Osamu Miura; Masahide Yamamoto
Journal:  In Vivo       Date:  2019 Sep-Oct       Impact factor: 2.155

6.  Methotrexate-associated orbital lymphoproliferative disorder in a patient with rheumatoid arthritis: a case report.

Authors:  Yuka Kobayashi; Kazuhiro Kimura; Youichiro Fujitsu; Kuniisa Shinkawa; Hiroko Muta; Koh-Hei Sonoda
Journal:  Jpn J Ophthalmol       Date:  2016-03-28       Impact factor: 2.447

7.  Composite Cutaneous Lymphoma (Iatrogenic Immunodeficiency-Associated Lymphoproliferative Disorder) in a Patient with Rheumatoid Arthritis Treated with Methotrexate: Staging and Evaluation of Response to Therapy with 18F-FDG PET/CT.

Authors:  William Makis; Anthony Ciarallo; Beatrice Wang; Milene Gonzalez-Verdecia; Stephan Probst
Journal:  Nucl Med Mol Imaging       Date:  2016-12-19

8.  Methotrexate-associated lymphoproliferative disorder complicated by severe acute respiratory failure and ileal perforation:a case report.

Authors:  Eiji Suzuki; Takashi Kanno; Satoru Kimura; Takumi Irie; Hajime Odajima; Kiyoshi Migita
Journal:  Fukushima J Med Sci       Date:  2018-06-19

9.  Hematologic malignancies in the Japanese patients with inflammatory bowel disease.

Authors:  Norimasa Fukata; Kazuichi Okazaki; Mika Omiya; Mitsunobu Matsushita; Mamoru Watanabe
Journal:  J Gastroenterol       Date:  2013-08-19       Impact factor: 7.527

10.  Malignancies and anti-TNF therapy in rheumatoid arthritis: a single-center observational cohort study.

Authors:  Nathalie Berghen; Laure-Anne Teuwen; Rene Westhovens; Patrick Verschueren
Journal:  Clin Rheumatol       Date:  2015-07-30       Impact factor: 2.980

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.